MacroGenics Strikes Second Oncology Partnership With Servier

21 Sep 2012

• By Paul Bonanos

The French pharma paid $20 million up-front for rights to option three preclinical programs, including drugs targeting both solid and liquid-tumor cancers.

Servier SA must like what it’s seen so far from MacroGenics Inc. The French pharma originally partnered with the antibody developer in late 2011 and then announced a new deal on Sept. 20. Under the latest deal, Servier has taken an option on three more programs from MacroGenics, all derived from the start-up’s bi-specific antibody platform.

Servier paid Rockville, MD-based MacroGenics $20 million up-front in the new deal, matching the initial component of the two companies’...